Wegovy^® (semaglutide injection) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in:¹

• Adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, dyslipidemia, or obstructive sleep apnea. 
• Pediatric patients aged 12 to less than 18 years with an initial BMI at the 95th percentile or greater for age and sex (see Table 1 below), a body weight above 60 kg (132 lbs), and an inadequate response to reduced-calorie diet and physical activity alone.

Wegovy^® is also indicated to reduce the risk of non-fatal myocardial infarction in adults with established CVD and BMI ≥27 kg/m².¹

Wegovy^® should not be used in combination with any other semaglutide-containing drug (e.g., Ozempic^®, Rybelsus^®) or any other GLP-1 receptor agonist.

Table 1: Body mass index (BMI) cut-off points for obesity by sex and age for patients aged 12 to less than 18 years

Please consult the Product Monograph at www.wegovypm-e.ca or click here for more information on:

• Contraindications in patients with a personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and patients who are pregnant or breastfeeding.
• The most serious warning and precaution regarding the risk of thyroid C-cell tumours.
• Other relevant warnings and precautions regarding cardiovascular effects; theoretical risk of dependence, tolerance, and/or abuse; risk of hypoglycemia with concomitant insulin or insulin secretagogue use (precaution with driving and operating machinery); gastrointestinal events leading to dehydration; delayed gastric emptying; acute pancreatitis (including fatal and non-fatal hemorrhagic or necrotizing pancreatitis); acute gallbladder disease; severe hypersensitivity reactions; retinal disorder in patients with type 2 diabetes; suicidal behaviour and ideation; aspiration in association with general anesthesia or sedation; acute kidney injury; use in hepatic insufficiency; end-stage renal disease; fertility; and recommendation for contraception use.
• Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.

The Product Monograph is also available by calling Novo Nordisk at 1-800-465-4334.